临界心血管风险患者中低密度脂蛋白胆固醇水平指导他汀治疗的成本效益
本研究基于美国健康与营养调查数据构建100个模拟队列(每队列100万40岁无ASCVD人群),评估在临界风险(10年ASCVD风险5.0%-7.4%)患者中依据LDL-C水平扩大他汀预防治疗的成本效益。
要点
- 临界风险且LDL-C 160-189 mg/dL者加用他汀可节省成本。
- 临界风险且LDL-C 130-159 mg/dL者加用他汀亦节省成本。
核心结论
- 对临界ASCVD风险且LDL-C 160-189 mg/dL的患者终身他汀治疗可节省成本。
- 对所有临界风险患者无论LDL-C水平如何,治疗可能具有高成本效益。
研究设计与样本
- 研究基于1999-2014年美国国家健康与营养调查,通过概率抽样创建100个模拟队列,每队列100万40岁无ASCVD受访者(男女各50%)。
- 采用CVD Policy Model微观模拟版本预测终身健康与成本结局,从美国医疗保健部门视角分析。
- 首次冠心病或卒中事件概率通过6项美国队列研究汇总分析估计并重新校准。
主要发现
- 在临界风险(10年ASCVD风险5.0%-7.4%)且LDL-C 160-189 mg/dL者中加用他汀可节省成本。
- 进一步治疗临界风险且LDL-C 130-159 mg/dL者亦可节省成本。
- 在相同年龄、10年风险及性别类别内,基线LDL-C水平较高者从他汀治疗中获得更多QALYs。
- 成本效益随LDL-C水平和10年ASCVD风险增加而提高。
关键数值与推荐
- 标准治疗:治疗所有10年ASCVD风险≥7.5%、糖尿病或LDL-C≥190 mg/dL的患者。
- 策略2:增加治疗临界风险且LDL-C 160-189 mg/dL者。
- 策略3:增加治疗临界风险且LDL-C 130-159 mg/dL者。
- 策略4:治疗所有10年ASCVD风险≥5.0%的其余患者。
- 主要结局增量成本效益比,QALYs和成本以2019年美元计,年贴现率3.0%。
临床怎么用
- 对于临界ASCVD风险(10年风险5.0%-7.4%)且LDL-C 160-189 mg/dL的患者,可考虑启动他汀治疗以节省医疗成本。
- 对于临界风险且LDL-C 130-159 mg/dL的患者,加用他汀亦可能节省成本。
- 对10年ASCVD风险≥5.0%的所有患者进行他汀治疗可能具有高成本效益。
局限性
- 研究基于模拟队列和模型假设,可能受模型参数不确定性影响。
- 事件概率来自6项美国队列研究的汇总分析并重新校准,外推需谨慎。
- 分析从美国医疗保健部门视角出发,结果可能不适用于其他医疗体系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: American College of Cardiology/American Heart Association cholesterol guidelines prioritize primary prevention statin therapy based on 10-year absolute risk (AR10) of atherosclerotic cardiovascular disease (ASCVD). However, given the same AR10, patients with higher levels of low-density lipoprotein cholesterol (LDL-C) experience greater absolute risk reduction from statin therapy. OBJECTIVES: To estimate the cost-effectiveness of expanding preventive statin treatment eligibility from standard care to patients at borderline risk (AR10, 5.0%-7.4%) for ASCVD and with high levels of LDL-C and to estimate cost-effectiveness of statin treatment across ranges of age, sex, AR10, and LDL-C levels. DESIGN, SETTING, AND PARTICIPANTS: This study evaluated 100 simulated cohorts, each including 1 million ASCVD-free survey respondents (50% men and 50% women) aged 40 years at baseline. Cohorts were created by probabilistic sampling of the 1999-2014 US National Health and Nutrition Examination Surveys from the perspective of the US health care sector. The CVD Policy Model microsimulation version projected lifetime health and cost outcomes. Probability of first-ever coronary heart disease or stroke event was estimated by analysis of 6 pooled US cohort studies and recalibrated to match contemporary event rates. Other model variables were derived from national surveys, meta-analyses, and published literature. Data were analyzed from May 15, 2018, through June 10, 2019. EXPOSURES: Four statin treatment strategies were compared: (1) treat all patients with AR10 of at least 7.5%, diabetes, or LDL-C of at least 190 mg/dL (standard care); (2) add treatment for borderline risk and LDL-C levels of 160 to 189 mg/dL; (3) add treatment for borderline risk and LDL-C levels of 130 to 159 mg/dL; and (4) add treatment for remainder of patients with AR10 of at least 5.0%. Statin treatment was also compared with no statin treatment in age, sex, AR10, and LDL-C strata. MAIN OUTCOMES AND MEASURES: Lifetime quality-adjusted life-years (QALYs) and costs (2019 US dollars) were projected and discounted 3.0% annually. The primary outcome was the incremental cost-effectiveness ratio. RESULTS: In these 100 simulated cohorts, each with 1 million patients aged 40 years at baseline (50% women and 50% men), adding preventive statins to individuals with borderline AR10 and LDL-C levels of 160 to 189 mg/dL would be cost-saving; further treating borderline AR10 and LDL-C levels of 130 to 159 mg/dL would also be cost-saving; and treating all individuals with AR10 of at least 5.0% would be highly cost-effective ($33 558/QALY) and would prevent the most ASCVD events. Within age, AR10, and sex categories, individuals with higher baseline LDL-C levels gained more QALYs from statin therapy. Cost-effectiveness increased with LDL-C level and AR10. CONCLUSIONS AND RELEVANCE: In this study, lifetime statin treatment of patients in a hypothetical cohort with borderline ASCVD risk and LDL-C levels of 160 to 189 mg/dL was found to be cost-saving. Results suggest that treating all patients at borderline risk regardless of LDL-C level would likely be highly cost-effective.
引用
- Kohli-Lynch CN, Bellows BK, Thanassoulis G, et al. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. JAMA Cardiol. 2019. PMID: 31461121. doi:10.1001/jamacardio.2019.2851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。